NASDAQ:NPSP

NPS Pharmaceuticals (NPSP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NPSP stock logo

About NPS Pharmaceuticals Stock (NASDAQ:NPSP)

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company’s second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

NPSP Stock News Headlines

Arena Pharmaceuticals
NPSP Historical Data
War Over Taiwan? Protect Your Wealth NOW
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
NPS Stock Gaps Down On Today's Open (NPSP)
War Over Taiwan? Protect Your Wealth NOW
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
Enzon and NPS Pharma Call Off Merger
Krispy Kreme Doughnuts (DNUT)
See More Headlines
Receive NPSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NPS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/18/2015
Today
4/26/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:NPSP
CUSIP
62936P10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

NPSP Stock Analysis - Frequently Asked Questions

How were NPS Pharmaceuticals' earnings last quarter?

NPS Pharmaceuticals Inc (NASDAQ:NPSP) posted its earnings results on Wednesday, February, 18th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.06 by $0.08. The biopharmaceutical company had revenue of $66.70 million for the quarter, compared to the consensus estimate of $69.30 million.

What other stocks do shareholders of NPS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NPS Pharmaceuticals investors own include Gilead Sciences (GILD), General Electric (ge), Intercept Pharmaceuticals (ICPT), Pharmacyclics (PCYC), Pfizer (PFE), Alkermes (ALKS), 3D Systems (DDD), FireEye (FEYE) and GW Pharmaceuticals (GWPH).

This page (NASDAQ:NPSP) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners